BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
BELBUCA® Net Revenues Increased 76% Over 1Q17 Achieved Significant Prescription Growth Increase of 55% for BELBUCA in 1Q18 vs 1Q17 Achieved Company Total Net Revenue of $11.3 Million for 1Q18 Addition of New and Improved Managed Care Coverage BDSI …